New Website for Prostate Cancer
PRINCETON, NJ--Cytogen Corporation is sponsoring a new website on prostate cancer that highlights its diagnostic imaging agent ProstaScint. The agent is used in newly diagnosed patients at high risk for metastases and in postprostatectomy patients with a high suspicion of recurrence or spread.
PRINCETON, NJ--Cytogen Corporation is sponsoring a new website on prostate cancer that highlights its diagnostic imaging agent ProstaScint. The agent is used in newly diagnosed patients at high risk for metastases and in postprostatectomy patients with a high suspicion of recurrence or spread.
The website (www.prostascint.com) has features for both physicians and patients. It includes full prescribing information and assistance for physicians in selecting the best course of treatment. It gives physicians the ability to post scans of their cases on a password-protected teleradiology section. This allows physicians to post images and exchange information with colleagues for the purposes of clinical or technical discussion.
Among the sites features available to patients are the "Medical Minute," an interactive question and answer section; information on reimbursement and a reimbursement hotline; access to a tutorial on prostate cancer and one of the largest, searchable prostate cancer support group directories, giving patients and families access to information on local meetings across the United States.
A second website (www.cytogen.com) offers a comprehensive look at Cytogens services, including extensive information on Quadramet, the companys product for the treatment of bone pain resulting from cancer that has spread to the bone.
